Literature DB >> 10366011

Regulation of human D1 dopamine receptor function and gene expression in SK-N-MC neuroblastoma cells.

A Sidhu1, B Olde, N Humblot, K Kimura, N Gardner.   

Abstract

SK-N-MC human neuroblastoma cells express functional D1, but not D5, dopaminergic receptors. Stimulating cells with dopamine or the D1-selective agonist, SKF R-38393, rapidly (t(1/2) = 1 h) resulted in > 95% attenuation of dopamine-mediated accumulation of cyclic AMP, without any change in D1 dopamine receptor levels. Prolonged (> 4 h) exposure of cells to dopamine attenuated D1 receptor levels to 45-50% of control (t(1/2) = 8 h) and was accompanied by a loss of high-affinity binding sites. At the molecular level, the expression of D1 receptor messenger RNA was bimodal: an initial increase (by approximately 60%) of receptor messenger RNA within 2 h of treatment of cells with dopamine was followed by a decline to 50% below control messenger RNA levels. Low concentrations (1-10 nM) of dopamine also potentiated D1 messenger RNA levels (up to 48%), resulting in a twofold increase in receptor levels. Transfection studies with the cloned human D1 promoter construct, pGL-D1P, indicated that the up-regulation of D1 messenger RNA was due to activation of promoter by dopamine. The dopamine-mediated up-regulation of both D1 receptor messenger RNA and promoter was prevented by the D1-selective antagonist, SCH 23390. The results suggest that dopamine regulates D1 receptor gene and protein expression in a bimodal manner, partly through activation of the receptor promoter. Moreover, the effects of dopamine are independent of the second messenger, cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366011     DOI: 10.1016/s0306-4522(98)00555-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

2.  Cannabidiol inhibits methamphetamine-induced dopamine release via modulation of the DRD1-MeCP2-BDNF-TrkB signaling pathway.

Authors:  Baoyu Shen; Dongxian Zhang; Xiaofeng Zeng; Lina Guan; Genmeng Yang; Liu Liu; Jian Huang; Yuanyuan Li; Shijun Hong; Lihua Li
Journal:  Psychopharmacology (Berl)       Date:  2022-01-08       Impact factor: 4.530

3.  Developmental Deltamethrin Exposure Causes Persistent Changes in Dopaminergic Gene Expression, Neurochemistry, and Locomotor Activity in Zebrafish.

Authors:  Tiffany S Kung; Jason R Richardson; Keith R Cooper; Lori A White
Journal:  Toxicol Sci       Date:  2015-04-24       Impact factor: 4.849

4.  Cannabidiol prevents methamphetamine-induced neurotoxicity by modulating dopamine receptor D1-mediated calcium-dependent phosphorylation of methyl-CpG-binding protein 2.

Authors:  Baoyu Shen; Ruilin Zhang; Genmeng Yang; Yanxia Peng; Qianyun Nie; Hao Yu; Wenjuan Dong; Bingzheng Chen; Chunhui Song; Yan Tian; Lixiang Qin; Junjie Shu; Shijun Hong; Lihua Li
Journal:  Front Pharmacol       Date:  2022-09-06       Impact factor: 5.988

5.  A synergistic approach towards understanding the functional significance of dopamine receptor interactions.

Authors:  Pratima Pandey; Mahlet D Mersha; Harbinder S Dhillon
Journal:  J Mol Signal       Date:  2013-12-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.